Deerland shared concerns with Gingrey relating to FDA draft guidance.
Deerland Enzymes (Kennesaw, GA) welcomed Georgia Congressman Phil Gingrey to its facility last month. The company reports that it shared concerns with the Congressman relating to current tax policies and FDA’s impending new dietary ingredient (NDI) draft guidance.
As companies await clarity to facilitate the process for establishing NDIs, Deerland Enzymes says that FDA’s current regulatory approach creates innovation challenges more akin to food additive regulations.
“We greatly appreciate Congressman Gingrey taking time out of his busy schedule to tour our facility and truly listen to the challenges we face in our industry,” said company CEO Scott Ravech. “I felt he sincerely understood our concerns and will support us to the best of his ability.”
Deerland Enzymes is a supplier of plant, animal, fungal, and bacterial-sourced enzymes.
The Nutritional Outlook Podcast Episode 35: Prioritizing Women's Health Research and Innovation
October 28th 2024On this month's episode of the Nutritional Outlook Podcast, Cepham's founder and president, Anand Swaroop, discusses the company's recent announcement to prioritize women's health research and innovation.
The Nutritional Outlook Podcast Episode 34: Demystifying Prebiotics and Postbiotics
September 30th 2024In this episode of the Nutritional Outlook Podcast we are looking back on a webcast Nutritional Outlook hosted in May, called “Demystifying the Prebiotic and Postbiotic Markets.” During that event, Sandra Saville, director of education and communication for the International Probiotics Association and Dr. Jessica A. Younes, scientific director of the International Probiotics Association debunked myths about prebiotic and postbiotics, and defined the respective categories to help manufacturers better understand how to responsibly formulate and market prebiotic and postbiotic products.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.